Association of HLA -A, -B and -DRB1 alleles with hematological diseases in Vojvodina

Major histocompatibility complex (MHC) genes are involved in various mechanisms of pathogenesis and immunoediting of hematological diseases. This study aimed to investigate the association between HLA -A, -B and -DRB1 alleles with hematological diseases. In this study, we performed DNA-based HLA typing by polymerase chain reaction analysis with sequence-specific primers (PCR-SSP) to distinguish HLA-A, -B, and -DRB1 alleles. Eighty-two patients with hematological diseases (29 with acute lymphoblastic leukemia (ALL), 19 with acute nonlymphoblastic leukemia (ANLL), 5 with chronic myelogenous leukemia (CML), 2 with chronic lymphocytic leukemia (CLL), 9 with myelodysplastic syndrome (MDS), 9 with lymphomas (M.Hodgkin (HL) and non-Hodgkin (NHL)), 7 with aplastic anemia (AA) and 2 with multiple myeloma (MM)), were included in the study and compared with 111 healthy blood donors, residents from Vojvodina, evaluating the strength of the observed associations by measuring the aetiologic and preventive fractions. Among the alleles significantly associated with hematological diseases, HLA-A*24 showed an aetiologic fraction higher than those of HLA-A*26 and A*25 (RR=1.027, EF=1.233, RR=1.047, EF=1.141 and RR=1.213, EF=0.910).Negative association with significant preventive fraction was observed with HLA-B*18 and HLA-DRB1*11 alleles, with RR=0.400, PF=0.179 and RR=0.587, PF=0.176. Our results suggest that HLA-A*24, A*26 and A*25 as associated more frequently than other specificities with a hypothetical disease predisposing genes, may play a role in the pathogenesis of hematological diseases. Geni glavnog kompleksa histokompatibilnosti (MHC) su ukljuceni u razlicite mehanizme etiopatogeneze i imunoloskog nadzora hematoloskih bolesti. Cilj ove studije je da se istrazi udruzenost HLA-A,-B i -DRB1 alela sa hematoloskim bolestima. U ovoj studiji primenjena je molekulska metoda HLA tipizacije putem lancane reakcije polimeraze sa prajmerima specificnim za sekvencu (PCR-SSP) za determinisanje HLA-A,-B i -DRB1 alela. Osamdeset-dva bolesnika sa hematoloskim oboljenjima (29 sa akutnom limfoblastnom leukemijom (ALL), 19 sa akutnom nelimfoblastnom leukemijom (ANLL), 5 sa hronicnom mijelogenom leukemijom (CML), 2 sa hronicnom limfocitnom leukemijom (CLL), 9 sa mijelodisplasticnim sindromom (MDS), 9 sa limfomima (M.Hodgkin (HL) i Non-Hodgkin (NHL)), 7 sa aplasticnom anemijom (AA) i 2 sa multiplim mijelomom (MM)), su ukljuceni u studiju. Kontrolna grupa od 111 zdravih dobrovoljnih dava